Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the firm’s price target on Gilead to $151 from$147 with an Overweight rating on the shares. The firm informed investors that the regulatory and political uncertainties currently weighing on biopharma are expected to subside. As these policy overhangs fade, Morgan Stanley anticipates a shift in market attention back to the industry’s core financial and operational performance. Later, on ...